Retro Biosciences
Coverage of Retro Biosciences in the Nexus archive.
- STAT+: EU and US advisers split over AstraZeneca breast cancer drug
EU and US regulatory advisers have diverged in their assessment of AstraZeneca's breast cancer drug, signaling potential approval challenges. The disagreement highlights different regulatory approaches between the two regions on this oncology treatment.
- STAT+: Longevity startup Retro Biosciences says latest fundraising values it at $1.8 billion
Retro Biosciences, a longevity startup backed by OpenAI CEO Sam Altman, has raised funding at a $1.8 billion valuation. The company aims to add 10 healthy years to human lifespan through gene therapies and cell replacement therapies. The company is currently running its first clinical trial for an Alzheimer's disease treatment, with positive results and data expected around August.
- Guarding biotech from China and big bets in longevity
STAT's Breakthrough Summit West brought together leaders in healthcare and science to discuss biotech developments. Key topics included BridgeBio's research publication concerns and Retro Biosciences' progress toward clinical trials, with focus on AI's role in drug development.